Michelle Kim, MD
Radiation Oncology · Ann Arbor, MINPI 1972777175
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $1,275 of the $1,720 with a category attached, or 74.1%. Blue Earth Diagnostics accounts for 83.1% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $1,275 and has fallen 80.3% since, to $251 in 2025.
Across 5 payments — averaging $344.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Blue Earth Diagnostics$1K
- Telix Pharmaceuticals$251
- Mevion_medical_systems_inc$39
Across 21 payments — averaging $16,778 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Blue Earth Diagnostics$352K
What the payments were for
- Speaking & faculty fees$1,27574%
- Food & beverage$44526%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Blue Earth Diagnostics | 2 | $1,430 |
| Telix Pharmaceuticals | 2 | $251 |
| Mevion_medical_systems_inc | 1 | $39 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Axumin$1,430
How this compares
$1,720 in reported general payments places this provider in the 75th percentile of 198 radiation oncology providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Memantine Hcl | 11 | $127 |
| Dexamethasone | 12 | $64 |
Paid to pharmacies, not to this prescriber.
Other radiation oncology in Ann Arbor
- Daniel WahlAnn Arbor$42K
- Daniel ChangAnn Arbor$38K
- Shruti JollyAnn Arbor$30K
- James KaneAnn Arbor$19K
- Theodore LawrenceAnn Arbor$12K
- Michelle MierzwaAnn Arbor$2K
- Michael GreenAnn Arbor$2K
- Sean MillerAnn Arbor$1K
- Frank ViciniPontiac$231K
- Thomas BoikeClarkston$171K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.